Essential oil for improving glycolipid metabolism, and preparation method and application thereof

Abstract

This invention discloses an essential oil for improving glucose and lipid metabolism, its preparation method, and its application, belonging to the field of plant essential oil pharmaceutical technology. This invention reveals for the first time the significant effect of a compound formula composed of lemon myrtle essential oil as the principal ingredient, supplemented with other synergistic plant essential oils, on improving glucose and lipid metabolism (especially obesity and non-alcoholic fatty liver disease). The essential oil contains ≥80% total citral (geranialdehyde + neraldehyde), prepared through pretreatment (pulverization), soaking, distillation, and drying steps; the process is simple and easy to produce. This invention is adaptable to various dosage forms such as oral soft capsules and topical roll-on products, and innovatively develops a nanoemulsion form, increasing its oral bioavailability by 2 times. The product protection scope of this invention is clear, the process is stable, and the application scenarios are well-defined, providing a new option for developing safe and effective natural-derived drugs or health products for treating glucose and lipid metabolism disorders, and has significant application value.

Description

Technical Field

[0001] This invention belongs to the field of pharmaceutical technology, specifically relating to a lemon myrtle essential oil for improving obesity and non-alcoholic fatty liver, its preparation method and application, especially focusing on multi-dosage form adaptation, compound synergy and integration of cutting-edge technologies. Background Technology

[0002] Glucose and lipid metabolism disorders are a core pathological state characterized by imbalances in the uptake, storage, synthesis, and catabolism of carbohydrates and lipids in the body. They are the common pathological basis for major metabolic diseases such as obesity, type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), atherosclerosis, and metabolic syndrome. With changes in modern lifestyles, the incidence of glucose and lipid metabolism disorders and related diseases has been rapidly increasing globally, becoming a pressing public health issue. The global obese population has exceeded 1 billion, and the number of people with type 2 diabetes has surpassed 537 million. The global prevalence of NAFLD is approximately 25%, and the patient population is trending younger, with a prevalence of approximately 15% in the 18-30 age group. These diseases not only severely impact patients' quality of life but also easily lead to serious complications such as cardiovascular events, cirrhosis, and liver cancer, placing a huge economic burden on global healthcare systems. Medical expenditures related to type 2 diabetes alone exceed US$800 billion annually.

[0003] Currently, first-line clinical treatments mainly rely on chemically synthesized drugs, but these have the following significant limitations: 1. Single target. Statins (used to lower lipids) block cholesterol synthesis by inhibiting HMG-CoA reductase, and metformin (used to lower blood sugar) works by inhibiting hepatic glycogen output and improving peripheral insulin sensitivity. The above drugs are all single-target regulators, which are difficult to comprehensively correct the multidimensional imbalance of the glucose and lipid metabolism network; 2. Safety issues. Long-term use of statins can cause muscle toxicity (such as myalgia and rhabdomyolysis) and abnormal liver function. Some meta-analyses have shown that they may increase the risk of new-onset diabetes. Metformin often causes gastrointestinal adverse reactions such as diarrhea and nausea. Its rare but serious risk of lactic acidosis limits its use in patients with renal insufficiency. Other drugs, such as SGLT2 inhibitors and GLP-1 receptor agonists, have their own advantages, but they also have problems such as hypoglycemia, urinary tract infection, high cost, or inconvenient administration. 3. Poor patient compliance. The safety risks of long-term medication and the limitations of controlling a single indicator lead to a high discontinuation rate (approximately 30%-40%), resulting in significant unmet clinical needs.

[0004] Against this backdrop, plant essential oils have garnered widespread attention due to their natural origin and diverse bioactivities. Plant essential oils are volatile aromatic secondary metabolites extracted from plants, characterized by their small molecular weight, ease of penetration through biological barriers, and synergistic effects across multiple targets, making them highly promising in the field of metabolic regulation. For example, peppermint essential oil has been reported to improve energy metabolism, while cinnamon essential oil has shown potential in regulating insulin sensitivity.

[0005] Lemon myrtle (Aloysia citrodora) is a South American plant with aromatic properties. The main component of its essential oil is citral (including geranialdehyde and neraldehyde isomers), and it also contains monoterpenoids such as limonene and linalool.

[0006] Current research has confirmed that lemon myrtle essential oil possesses significant antibacterial, antifungal, and antioxidant activities, and therefore has practical applications in daily chemical products, food preservation, and aromatherapy. However, existing technologies for the application of lemon myrtle essential oil still have the following key gaps: 1. Deficiencies in Research Direction. Existing literature and patents mostly focus on its antibacterial and preservative uses, lacking systematic and in-depth research on its metabolic regulatory activities. In the existing technology, there are no reports of in vivo experiments on the regulation of key physiological and pathological aspects of lemon myrtle essential oil, such as fat synthesis and decomposition, insulin sensitivity, and hepatic lipid metabolism. Although a few studies suggest that citral has anti-inflammatory potential, there are no publicly available reports on the overall in vivo regulatory effects of lemon myrtle essential oil on glucose and lipid metabolism.

[0007] 2. Lack of pharmaceutical applications. In the existing technology, there are no publicly available technical solutions for using lemon myrtle essential oil alone or as a main active ingredient to prevent, alleviate, or treat disorders of glucose and lipid metabolism and related diseases (such as obesity and non-alcoholic fatty liver disease), nor are there any technical indications that this essential oil possesses such pharmaceutical applications.

[0008] 3. Insufficient dosage form development. Most existing plant essential oil products exist in the form of simple diluted oils or aromatherapy preparations, with low bioavailability (e.g., oral bioavailability is usually less than 10%), and there is a lack of specific dosage form development targeting glucose and lipid metabolism (such as oral soft capsules, transdermal preparations, nanoemulsions, etc.), which significantly restricts their clinical translation and expansion of application scenarios.

[0009] In summary, current technologies cannot meet the demand for multi-target, high-safety treatment of glucose and lipid metabolism disorders. The metabolic regulatory potential of lemon myrtle essential oil has not been fully explored, and there are significant gaps in its pharmaceutical applications and the development of targeted dosage forms. Therefore, developing a novel formulation with lemon myrtle essential oil as the core active ingredient, possessing multi-target synergistic regulatory activity, high bioavailability, and adaptability to various dosage forms is of great significance for solving the aforementioned technical problems and has promising clinical application prospects. Summary of the Invention

[0010] The present invention aims to provide an essential oil for improving glucose and lipid metabolism, and also provides a method for preparing the essential oil and its application in the preparation of products related to improving glucose and lipid metabolism.

[0011] This invention verifies the significant effects of this essential oil on regulating body weight, liver lipid accumulation, and glucose metabolism through in vitro and in vivo experiments, providing a scientific basis for its medicinal and health care applications.

[0012] To achieve the above objectives, the present invention adopts the following technical solution: In a first aspect, the present invention provides an essential oil for improving glucose and lipid metabolism, wherein the core active ingredient of the essential oil is lemon myrtle essential oil. The essential oil is a compound essential oil comprising lemon myrtle essential oil and at least one auxiliary essential oil.

[0013] Preferably, the auxiliary essential oil is selected from one or more of the following: Amomum villosum essential oil, Costus root essential oil, Cinnamon essential oil, Eupatorium fortunei essential oil, Grapefruit essential oil, Lemon essential oil, Tangerine peel essential oil, Bitter orange essential oil, Bergamot essential oil, Clove essential oil, Patchouli essential oil, Sichuan pepper essential oil, Green tangerine peel essential oil, Red mandarin orange essential oil, Cardamom essential oil, Perilla essential oil, Citrus essential oil, Fennel essential oil, Atractylodes macrocephala essential oil, Atractylodes lancea essential oil, Artemisia capillaris essential oil, Frankincense essential oil, Citrus aurantium essential oil, Citrus aurantium peel essential oil, Ginger essential oil, Grapefruit essential oil, Peppermint essential oil, Lemongrass essential oil, Oak essential oil, and Cypress essential oil.

[0014] Preferably, in the compound essential oil, the volume percentage of lemon myrtle essential oil is controlled to be 50%-90%.

[0015] In a second aspect, the present invention provides a method for preparing the essential oil described in the first aspect, the method comprising the following steps: The lemon myrtle essential oil is prepared by the following steps: S1. Pretreatment: Crush fresh or shade-dried lemon myrtle leaves and pass them through a 40-60 mesh sieve. S2. Soaking: Soak the crushed lemon myrtle leaves from step S1 in double-distilled water to obtain a lemon myrtle mixture. S3. Distillation: The lemon myrtle mixture soaked in step S2 is distilled. S4. Drying: The lemon myrtle fraction obtained from distillation is dehydrated with anhydrous sodium sulfate or dried by molecular distillation to obtain lemon myrtle essential oil.

[0016] Preferably, the ratio of lemon myrtle leaves to double-distilled water in the soaking process in step S2 is 1g:6-8ml; Preferably, the distillation conditions in step S2 are: temperature 80-90℃, pressure 250-350mbar, and time 5-6h; Thirdly, the present invention provides the use of the essential oils as described in the first aspect in the preparation of formulations for improving glucose and lipid metabolism.

[0017] Preferably, the formulation is used for the prevention or treatment of obesity and / or non-alcoholic fatty liver disease.

[0018] Preferably, the dosage form is an oral preparation, a topical preparation, or an aromatherapy preparation; wherein, the oral preparation includes oral soft capsules, microcapsules, tablets, suspensions, pellets, oral liquids, and nanoemulsions; the topical preparation includes creams, gels, skin sprays, transdermal patches, and roll-on preparations; and the aromatherapy preparation includes aromatherapy sprays, diffusers, and olfactory sticks.

[0019] The oral soft capsules improve the stability and oral bioavailability of essential oils; the nanoemulsions enhance the solubility and transdermal permeability of essential oils; the roll-on formulations facilitate precise application; the transdermal patches enable sustained-release administration; and the aromatherapy preparations regulate physiological functions through the olfactory pathway. The pharmaceutical excipients may include fillers, disintegrants, lubricants, preservatives, transdermal penetration enhancers, emulsifiers, or capsule materials, the specific selection depending on the dosage form and route of administration.

[0020] Preferably, the formulation is used for the prevention or treatment of obesity and / or non-alcoholic fatty liver disease.

[0021] This invention also provides the application of the lemon myrtle essential oil in the preparation of health products or functional foods for the prevention or improvement of glucose and lipid metabolism disorders. The health products or functional foods use lemon myrtle essential oil as the active ingredient, supplemented with pharmaceutically acceptable excipients (including but not limited to vitamins, dietary fiber, prebiotics, and other nutritional components), and can be prepared in oral formulations, including but not limited to soft capsules, oral liquids (such as beverages), powders, and nutrition bars. The lemon myrtle essential oil has a small molecular weight, is easily absorbed by the human body, can accelerate body circulation, promote metabolism, thereby regulating the balance of glucose and lipid metabolism, preventing or improving glucose and lipid metabolism disorders, maintaining metabolic health, and reducing the risk of metabolic syndrome.

[0022] The beneficial effects of this invention are: (1) Through systematic in vitro and in vivo experiments, this invention reveals and verifies for the first time the significant effect of lemon myrtle essential oil in improving glucose and lipid metabolism, breaking through the traditional cognitive limitations of this essential oil, which is limited to antibacterial and antioxidant uses. This discovery provides a new scientific basis and application direction for the in-depth development of lemon myrtle essential oil, especially in the field of metabolic disease drugs, and fills the existing technological gap.

[0023] (2) Animal experiments showed that the lemon myrtle compound essential oil of the present invention can synergistically regulate glucose and lipid metabolism disorders in multiple dimensions. Specifically, in terms of body weight and lipid metabolism, it can effectively inhibit the weight gain of obese model mice induced by a high-fat diet; in terms of liver tissue protection, it can significantly improve liver lipid degeneration, as shown by the results of H&E staining and OilRed O staining of liver tissue sections, effectively reducing lipid droplet accumulation and inflammatory infiltration in hepatocytes, and showing a clear intervention effect on the formation and development of non-alcoholic fatty liver disease (NAFLD).

[0024] (3) Compared to the potential side effects of long-term use of existing chemical drugs (such as statins and metformin), such as liver and kidney damage and gastrointestinal reactions, the lemon myrtle essential oil used in this invention is derived from natural plants, and its raw material, lemon myrtle leaves, has obtained currently valid food compliance certification. This provides a high-quality candidate substance for developing alternative or complementary therapies with fewer side effects and better patient compliance, meeting the current market's urgent demand for natural health products.

[0025] (4) This invention expands the application scope and dosage form selection of lemon myrtle compound essential oil. It can be used not only in pharmaceuticals but also in health foods and functional foods. The dosage forms cover conventional forms such as oral soft capsules, transdermal drug delivery preparations, and aromatherapy preparations, as well as cutting-edge forms such as nanoemulsions and transdermal drug delivery patches, which can adapt to the usage scenarios and needs of different groups of people (such as oral administration for daily conditioning, external rollerballs for local care, and microcapsule patches for long-term intervention). Its natural properties, compound synergy, multi-effect, and dosage form diversity give it broad market potential in the health industry. The dosage forms are oral preparations, external preparations, or aromatherapy preparations; wherein, the oral preparations include oral soft capsules, microcapsules, tablets, suspensions, drops, oral liquids, and nanoemulsions; the external preparations include creams, gels, skin sprays, transdermal drug delivery patches, and rollerballs; the aromatherapy preparations include aromatherapy sprays, diffusers, and olfactory sticks. Attached Figure Description

[0026] Figure 1 This is a graph showing the weight changes of mice in each group in Experiment Example 1 of this invention.

[0027] Figure 2 This is a graph showing the rate of change in body weight of mice in each group in Experiment Example 1 of this invention.

[0028] Figure 3 The liver index diagrams of mice in each group in Experiment Example 1 of this invention are shown.

[0029] Figure 4 These are H&E stained pathological sections of mouse liver tissue from each group in Experiment Example 1 of this invention.

[0030] Figure 5The images show Oil Red O staining of liver tissue from mice in each group in Experiment Example 1 of this invention. Detailed Implementation

[0031] To make the technical means, creative features, objectives and effects of this invention easier to understand, the invention will be further described below in conjunction with specific embodiments.

[0032] Examples 1-3: Lemon Myrtle Essential Oil Blend Example 1: Lemon Myrtle Compound Essential Oil 1. Preparation of compound essential oil, which is made by uniformly mixing lemon myrtle essential oil and cinnamon essential oil in a volume ratio of 1:1 (lemon myrtle essential oil).

[0033] Example 2: Lemon Myrtle Compound Essential Oil 2. The compound essential oil is prepared by uniformly mixing lemon myrtle essential oil and bergamot essential oil in a volume ratio of 1:1.

[0034] Example 3: Lemon Myrtle Compound Essential Oil 3. The compound essential oil is prepared by uniformly mixing lemon myrtle essential oil, cinnamon essential oil and bergamot essential oil in a volume ratio of 1:1:1.

[0035] Example 4 Preparation of lemon myrtle compound essential oil nanoemulsion (1) Formula: 10% essential oil, 5% Tween 80, 3% glycerin, 82% water; (2) Preparation: High-speed stirring + high-pressure homogenization, particle size 100-200nm; Example 5 Preparation of Lemon Myrtle Compound Essential Oil Soft Capsules Raw material composition (based on 1000 capsules) Lemon Myrtle Blend Essential Oil: 150g (Composition: 65% lemon myrtle essential oil, 15% cinnamon essential oil, 10% grapefruit essential oil, and 10% flaxseed oil, all meeting food-grade quality standards) Oil phase matrix: 300g soybean oil (meets pharmaceutical grade quality standards) Emulsifier: 20g soybean lecithin (meets food-grade quality standards) Antioxidant: Vitamin E 5g (meets food-grade quality standards) Capsule shell materials: 120g gelatin, 40g glycerin, 120g purified water, 0.15g ethylparaben (all meeting pharmaceutical grade quality standards) 2. Preparation steps (1) Preparation of contents: Add lemon myrtle compound essential oil, soybean oil, lecithin and vitamin E to a stainless steel mixing tank, turn on the stirring (speed set to 150 rpm), heat to 42℃ and keep stirring for 25 minutes until the system is uniform and transparent; then filter through a 200-mesh stainless steel screen to remove impurities and set aside.

[0036] (2) Preparation of capsule shell solution: Add gelatin, glycerin, purified water and ethylparaben to a sol tank, heat to 65°C, stir (speed set to 80 rpm) until completely dissolved, degas under vacuum for 15 minutes (vacuum degree controlled at -0.08 MPa), and keep warm at 60°C for later use.

[0037] (3) Soft capsule compression: A rotary soft capsule compression machine is used. The temperature of the contents hopper is adjusted to 45℃ and the temperature of the capsule shell hopper is adjusted to 62℃. The compression speed is set to 28 revolutions / minute. Oval soft capsules with a single weight of about 0.5g (contents about 0.475g and capsule shell about 0.025g) are obtained.

[0038] (4) Drying and quality inspection: The pressed soft capsules were transferred to a ventilated drying room and dried for 22 hours at 26°C and 38% relative humidity. After drying, the capsules were screened according to the appearance inspection items under the soft capsule section of the Chinese Pharmacopoeia (2025 edition). The finished products with intact appearance, no leakage and no deformation were retained. The retention rate of active ingredients of lemon myrtle essential oil reached 86.2% by high performance liquid chromatography (HPLC), which met the quality standards.

[0039] 3. Product Characteristics The soft capsules prepared in this embodiment have a round and smooth appearance, and the contents are uniform without layering. The accelerated stability test (40°C, 75% relative humidity, 6 months) verified that there was no oxidative rancidity or leakage, making them suitable for long-term storage and convenient daily consumption.

[0040] Note: The ratio of compound essential oils in this embodiment is an exemplary selection, and can be adjusted according to actual production needs; all raw materials meet the corresponding quality standards (food grade / pharmaceutical grade), and the preparation process strictly follows GMP specifications to ensure product safety and efficacy.

[0041] Example 6 Preparation of Lemon Myrtle Compound Essential Oil Roll-on 1. Raw material composition (based on 100 vials, 10mL per vial), as shown in Table 1.

[0042] Table 1. Formula for Lemon Myrtle Compound Essential Oil Roll-on Product 2. Preparation steps (1) Premixing stage: Add lemon myrtle compound essential oil and jojoba oil to a stainless steel mixing tank in sequence, and stir at 120 rpm for 10 minutes at room temperature to ensure that the oil phase components are evenly dispersed.

[0043] (2) Solubilization and stabilization stage: Slowly add vitamin E, adjust the speed to 150 rpm and continue stirring for 15 minutes until the system is clear and transparent (no layering, no precipitation).

[0044] (3) Filtration and sterilization stage: The mixture is first pre-filtered with a 0.45μm oleophilic filter membrane to remove large particulate impurities (such as solid particles remaining in the raw materials) in the oil solution; then filtered through a 0.22μm oleophilic microporous filter membrane (such as polytetrafluoroethylene PTFE or polypropylene PP) to remove impurities and microorganisms, and the clear filtrate is collected (operation must be carried out in a sterile environment).

[0045] (4) Filling and sealing stage: Place the sterile ball bottle that has been sterilized by ultraviolet light for 30 minutes in advance on the filling line, accurately fill each bottle with 10mL of filtrate, tighten the cap with ball, and label it to get the finished product.

[0046] 3. Product Characteristics Appearance and user experience: A pale yellow, clear, and transparent liquid with a smooth, non-sticky rollerball applicator; it feels refreshing and non-greasy on the skin, emitting a fresh scent of lemon and peach wood with a gentle, cooling sensation from mint, and absorbs quickly.

[0047] Stability verification: After accelerated stability testing (40℃, 75% relative humidity, 3 months), there was no stratification, discoloration, or off-odor, and the retention rate of active ingredients reached over 95%.

[0048] Hygiene indicators: Meets the requirements for external preparations in the "Cosmetic Safety Technical Specifications" (2015 edition): total bacterial count ≤100 CFU / mL, total mold and yeast count ≤10 CFU / mL, and no pathogenic bacteria detected.

[0049] Note: The compound essential oil ratio in this embodiment is an exemplary selection. In actual production, it can be adjusted according to efficacy requirements. All raw materials must meet the corresponding quality standards, and the preparation process follows the GMP specifications for topical preparations to ensure product safety and effectiveness.

[0050] Experimental Example 1: The effect of compound essential oils on improving glucose and lipid metabolism in obese model mice. (1) Establishment of a rat obesity model Adult healthy male SD rats (purchased from Nanchang Kaiyihe Biotechnology Co., Ltd.), with similar body weight and body fat percentages, were randomly divided into four groups (n=8 per group) after one week of acclimatization feeding: normal control group, model group, orlistat (positive control), lemon myrtle essential oil topical application group, lemon myrtle essential oil oral administration group, lemon myrtle compound essential oil 1 topical application group, lemon myrtle compound essential oil 2 topical application group, and lemon myrtle compound essential oil 3 topical application group. Except for the normal control group, which was fed a regular diet, the other groups were fed a high-fat diet for model establishment. The rearing temperature was (24±2)℃, and the relative humidity was 50%. The light intensity was controlled at 70%, with 12 hours of light and 12 hours of darkness, for 8 consecutive weeks. The body weight of each rat was recorded every 3 days. The model was considered successful when the body weight of the model group rats differed from that of the normal group rats by 20%.

[0051] (2) Grouping and administration After successful modeling, the blank and model groups were given the same amount of physiological saline daily; the positive control was given 40 mg / kg orlistat (Hangzhou Sino-American East China Pharmaceutical Co., Ltd., H30019728) by gavage daily; the topical dose of lemon myrtle essential oil (including compound essential oil) was 1 ml / day, applied to the Shenque acupoint; the oral dose of lemon myrtle essential oil was 1 / 10 of the topical dose; the administration was carried out for 24 consecutive days.

[0052] (3) Recording and testing During the drug administration period, the rats' weight changes were recorded regularly. After the experiment, the rats' liver tissues were dissected and weighed, and the liver index (liver weight ÷ rat weight × 100%) was calculated and pathological analysis was performed.

[0053] (4) Liver pathological examination (H&E and Oil Red O) Liver tissue was fixed in a general-purpose fixative (Servicebio, G1101) for 24 hours. Subsequently, the tissue was dehydrated, embedded in paraffin, and sections were stained with routine H&E (Servicebio, G1004). Another portion of liver tissue was immersed in 30% sucrose (Beijing Kangpu Huiwei, WKPHW-ZT-25KG) solution for 48 hours, then dehydrated, embedded in OTC embedding medium (Servicebio, G6059-110ML), and sectioned (5 μm). These sections were washed with 60% isopropanol and stained with Oil Red O staining solution (Servicebio, G1015) according to the manufacturer's instructions. Finally, morphological changes were observed using a light microscope.

[0054] Results Analysis (1) such as Figure 1As shown, at the beginning of drug administration, the weight difference between the model group and the blank group was more than 20%, indicating that the model was successfully established. As the feeding time progressed, the weight of the rats in the model group showed a significant increasing trend, while the external and oral application of lemon myrtle essential oil and the compound essential oil 1-3 significantly reduced the weight of obese rats, showing an overall decreasing trend.

[0055] (2) Weight loss rate statistics: such as Figure 2 As shown, after 24 days of administration, the model's weight gain rate was 6.22%, while the weight loss rates of the topical and oral lemon myrtle essential oil groups were 2.36% and 4.67%, respectively. The weight loss rate of lemon myrtle compound essential oil 1-3 further increased.

[0056] (3) Liver index statistics The liver indexes of the control group, model group, orlistat group, essential oil topical group, and essential oil oral group were 2.67%, 5.10%, 4.39%, 4.20%, and 4.03%, respectively. Figure 3 As shown, compared with the model group, the liver index of the orlistat group, the essential oil-topical group, and the essential oil oral group all showed a significant decreasing trend. The liver index of the lemon myrtle compound essential oil 1-3 showed a more obvious decreasing trend and had statistically significant differences.

[0057] (4) Liver pathological analysis like Figure 4 The H&E staining results showed that the cells in the liver tissue sections of the blank group were neatly arranged and the overall staining was relatively uniform, ranging from pink to light pink. The liver tissue sections of the model group showed a large number of blank, unstained round vacuoles and focal or diffuse fatty liver characteristics, indicating that the fatty liver model was successfully established. In contrast, the blank and unstained round vacuoles in the liver tissue sections of the orlistat group, the topical essential oil group, and the oral essential oil group were significantly reduced, and the overall characteristics were closer to those of the blank control group, indicating that the drug could effectively improve the symptoms of fatty liver.

[0058] like Figure 5 The results of Oil Red O staining showed that the liver tissue sections in the blank group had a light counterstain background color with almost no bright red signal; the liver tissue sections in the model group showed a large number of diffuse or focal bright red areas, indicating that the model was successfully established; the sections in the orlistat group, the topical essential oil group, and the oral essential oil group had a lighter staining background, a relatively smaller area of ​​red lipid droplets, and a significant increase in non-fat blue staining areas, indicating that the drugs could significantly improve the symptoms of fatty liver.

[0059] The foregoing has shown and described the basic principles, main features, and advantages of the present invention. It will be apparent to those skilled in the art that the present invention is not limited to the details of the exemplary embodiments described above, and that the invention can be implemented in other specific forms without departing from its spirit or basic characteristics. Therefore, the embodiments should be considered exemplary and non-limiting in all respects, and the scope of the invention is defined by the appended claims rather than the foregoing description. Thus, it is intended that all variations falling within the meaning and scope of equivalents of the claims be included within the present invention.

[0060] Furthermore, it should be understood that although this specification describes embodiments, not every embodiment contains only one independent technical solution. This narrative style is merely for clarity. Those skilled in the art should consider the specification as a whole, and the technical solutions in each embodiment can also be appropriately combined to form other embodiments that can be understood by those skilled in the art.

Claims

1. An essential oil for improving glucose and lipid metabolism, characterized in that, The active ingredient in the essential oil includes lemon myrtle essential oil.

2. The essential oil according to claim 1, characterized in that, The essential oil is a compound essential oil containing lemon myrtle essential oil and at least one auxiliary essential oil.

3. The essential oil according to claim 2, characterized in that, The auxiliary essential oils are selected from one or more of the following: Amomum villosum essential oil, Costus root essential oil, Cinnamon essential oil, Eupatorium fortunei essential oil, Grapefruit essential oil, Lemon essential oil, Tangerine peel essential oil, Bitter orange essential oil, Bergamot essential oil, Clove essential oil, Patchouli essential oil, Sichuan pepper essential oil, Green tangerine peel essential oil, Red mandarin orange essential oil, Cardamom essential oil, Perilla essential oil, Citrus essential oil, Fennel essential oil, Atractylodes macrocephala essential oil, Atractylodes lancea essential oil, Artemisia capillaris essential oil, Frankincense essential oil, Fructus Aurantii Immaturus essential oil, Fructus Aurantii Immaturus essential oil, Ginger essential oil, Grapefruit essential oil, Peppermint essential oil, Lemongrass essential oil, Oak essential oil, and Cypress essential oil.

4. The essential oil according to claim 2, characterized in that, In the compound essential oil, lemon myrtle essential oil accounts for 50%-90% by volume.

5. A method for preparing the essential oil as described in claim 1, characterized in that, Includes the following steps: S1. Pretreatment: Crush fresh or shade-dried lemon myrtle leaves and pass them through a 40-60 mesh sieve. S2. Soaking: Soak the crushed leaves from step S1 in distilled water at a ratio of 1g:6-8ml; S3. Distillation: Distill the mixture after soaking in step S2 at 80-90℃ and 250-350mbar for 5-6 hours; S4. Drying: Dehydrate the lemon myrtle fraction obtained from distillation using anhydrous sodium sulfate or dry it by molecular distillation to obtain lemon myrtle essential oil.

6. The use of an essential oil according to any one of claims 1-4 or an essential oil prepared by the preparation method according to any one of claims 5 in the preparation of a preparation for improving glucose and lipid metabolism.

7. The application according to claim 6, characterized in that, The dosage form is an oral preparation, a topical preparation, or an aromatherapy preparation; wherein, the oral preparation includes oral soft capsules, microcapsules, tablets, suspensions, pellets, oral liquids, and nanoemulsions; the topical preparation includes creams, gels, skin sprays, transdermal patches, and roll-on preparations; and the aromatherapy preparation includes aromatherapy sprays, diffusers, and olfactory sticks.

8. The application according to claim 6, characterized in that, The formulation is used to prevent or treat obesity and / or non-alcoholic fatty liver disease.

9. The use of an essential oil as described in any one of claims 1-4 in the preparation of health products or functional foods for improving glucose and lipid metabolism.

Images